<div id="readability-page-1"><p>Shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) have received a consensus recommendation of &#34;Moderate Buy&#34; from the five ratings firms that are currently  covering the firm, MarketBeat.com reports. One research analyst  has rated the stock with a sell rating, three have issued  a buy rating and one  has issued  a strong buy rating on  the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $14.00.</p><p>A number of research firms recently weighed in on DSGN. Royal Bank Of Canada raised shares of Design Therapeutics from a &#34;sector perform&#34; rating to an &#34;outperform&#34; rating and increased their price objective for the stock from $6.00 to $13.00 in a research report on Thursday, November 20th. Leerink Partnrs upgraded Design Therapeutics from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Wednesday. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Design Therapeutics in a report on Wednesday, October 8th. Craig Hallum started coverage on Design Therapeutics in a report on Wednesday. They set a &#34;buy&#34; rating and a $15.00 target price for the company. Finally, Wall Street Zen upgraded shares of Design Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 8th.</p><div><p><span></span><span>Get <strong>Design Therapeutics</strong> alerts:</span></p></div><p><b>Read Our Latest Stock Analysis on DSGN</b></p><h2>Institutional Investors Weigh In On Design Therapeutics</h2><p>Several institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE grew its position in shares of  Design Therapeutics by 11.1% in the 2nd quarter. Bank of America Corp DE now owns 24,625 shares of the company's stock valued at $83,000 after buying an additional 2,459 shares during the last quarter.  Russell Investments Group Ltd. boosted its stake in  Design Therapeutics by 69.6% in the third quarter. Russell Investments Group Ltd. now owns 6,377 shares of the company's stock valued at $48,000 after acquiring an additional 2,618 shares in the last quarter.  Invesco Ltd. boosted its stake in  Design Therapeutics by 26.8% in the second quarter. Invesco Ltd. now owns 14,364 shares of the company's stock valued at $48,000 after acquiring an additional 3,033 shares in the last quarter.  MPM Bioimpact LLC grew its holdings in shares of  Design Therapeutics by 0.6% during the first quarter. MPM Bioimpact LLC now owns 562,943 shares of the company's stock worth $2,173,000 after purchasing an additional 3,396 shares during the last quarter.  Finally, JPMorgan Chase &amp; Co. increased its position in shares of  Design Therapeutics by 26.7% during the third quarter. JPMorgan Chase &amp; Co. now owns 23,221 shares of the company's stock worth $175,000 after purchasing an additional 4,896 shares in the last quarter. Hedge funds and other institutional investors own  56.64% of the company's stock. </p><h2>Design Therapeutics Trading Up 9.3%</h2><p>Shares of DSGN stock opened at $9.77 on Thursday. Design Therapeutics has a 12-month low of $2.60 and a 12-month high of $10.00. The business's 50 day moving average is $7.14 and its two-hundred day moving average is $5.44. The company has a market capitalization of $556.50 million, a P/E ratio of -8.21 and a beta of 1.63. </p><p>Design Therapeutics (NASDAQ:DSGN - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.04.  On average, research analysts predict that  Design Therapeutics will post -0.91 earnings per share for the current fiscal year. </p><h2>Design Therapeutics Company Profile</h2> (Get Free Report)<p>Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Design Therapeutics</li><li>Low PE Growth Stocks: Unlocking Investment Opportunities</li><li>MongoDB Just Posted a Blowout Quarter—But Is It Too Hot to Touch?</li><li>What is the S&amp;P 500 and How It is Distinct from Other Indexes</li><li>3 Stocks Poised to Benefit From Google’s AI Breakthough</li><li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li><li>Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFNHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFNHTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Design Therapeutics Right Now?</h2><p>Before you consider Design Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.</p><p>While Design Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

DSGN

<p>Design Therapeutics, Inc. (NASDAQ:DSGN) has received a consensus "Moderate Buy" rating from five brokerages, with an average price target of $14.00. Royal Bank Of Canada upgraded the stock to "outperform," raising its price target to $13.00. Institutional investors have adjusted their stakes, with Bank of America and JPMorgan Chase increasing their positions. The stock is trading at $9.77, with a market cap of $556.50 million. The company reported better-than-expected quarterly earnings, with an EPS of ($0.30).</p>

Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages